Challenge Most of the complications after open heart surgery are caused by excessive blood loss and clots (RBS). Patients that undergo open heart surgery lose 500 to 1500 ml of blood afterwards because of diffuse bleedings. The excessive blood loss and clots obstruct drains, cause heart fibrillations, re-operations and cardiac tamponades, effecting in the loss of 30,000 lives, 18,000 re-operations, 250,000 complications and € 15,5 billion incremental health care cost.
OPPORTUNITY The therapeutical value of Haermonics is in preventing unnecessary reoperations, reducing the number of blood transfusions and post-operative ICU-care. The Haermonics Flush monitors the patients’ status after surgery, giving the medical professional a better status of the patient, enabling the doctor to make better decisions. Haermonics flush is designed to save thousands of lives and billions in hospital costs.
Solution Haermonics developed a device which flushes the pericardial cavity (area around the heart) to evacuate blood and clots that are left behind after open heart surgery. The results of the two randomized clinical trials: 300 patients included are showing a blood loss reduction of 30% to 40% and zero tamponades in the flushed group versus 4 in the control group.
Status Haermonics technology has proven itself in 3 randomized studies in over 330 patients. Haermonics is currently closing a VC-investment round to enable further development of a CE-marked product, international Multi-centre studies and up scaling for market launch.